Amarin Co. plc (NASDAQ:AMRN) Director David M. Stack sold 13,174 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $18.00, for a total value of $237,132.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:AMRN opened at $17.60 on Thursday. Amarin Co. plc has a 52 week low of $2.35 and a 52 week high of $23.33. The company has a market capitalization of $5.59 billion, a P/E ratio of -45.13 and a beta of 1.15. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.84 and a current ratio of 2.20.
Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. Amarin had a negative return on equity of 450.07% and a negative net margin of 45.16%. The firm had revenue of $73.30 million for the quarter, compared to the consensus estimate of $67.30 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The firm’s revenue was up 67.0% on a year-over-year basis. On average, sell-side analysts anticipate that Amarin Co. plc will post -0.22 EPS for the current year.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Amarin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 8th. BidaskClub downgraded Amarin from a “buy” rating to a “hold” rating in a report on Thursday, March 21st. Stifel Nicolaus assumed coverage on Amarin in a report on Thursday, March 21st. They issued a “buy” rating and a $27.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Amarin in a report on Monday, April 1st. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.43.
COPYRIGHT VIOLATION WARNING: “David M. Stack Sells 13,174 Shares of Amarin Co. plc (AMRN) Stock” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/23/david-m-stack-sells-13174-shares-of-amarin-co-plc-amrn-stock.html.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.